Skip to main content

stock

KROS · Keros Therapeutics, Inc.

What Keros Therapeutics, Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live KROS price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on KROS.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
19,827,188 as of 2026-07-27 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
-675.8%
Net
-553.9%

Returns

ROE
-31.7%
ROA
-28.9%

Health

Current ratio
22.0x
Debt/equity
—

Deep value

NCAV
$241.60M
NCAV per share
$12.19
Price/NCAV
Locked
NNWC
$232.33M
NNWC per share
$11.72
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30$0—Gross profit: unreported by this company.-$30.94M-$28.71M
10-Q filed 2026-08-03
2026-03-31$367,000—Gross profit: unreported by this company.-$25.88M-$23.71M
10-Q filed 2026-08-03
Assembled from more than one filing; the filing above is only the newest of them.
2025-12-31$385,000—Gross profit: unreported by this company.-$29.27M-$23.46M
DEF 14A filed 2026-04-22
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2025-09-30$14.26M—Gross profit: unreported by this company.-$15.38M-$7.28M
10-Q filed 2025-11-05
2025-06-30$18.17M—Gross profit: unreported by this company.-$39.82M-$30.70M
10-Q filed 2026-08-03
2025-03-31$211.25M—Gross profit: unreported by this company.$152.04M$148.45M
10-Q filed 2026-08-03
Assembled from more than one filing; the filing above is only the newest of them.
2024-12-31$3.04M—Gross profit: unreported by this company.-$53.25M-$46.03M
DEF 14A filed 2026-04-22
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30$388,000—Gross profit: unreported by this company.-$58.66M-$52.96M
10-Q filed 2025-11-05
Assets
$287.60M
Equity
$262.32M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$244.06M$67.57M$87.01M$105.95M
2024-12-31$3.55M-$210.83M-$187.35M-$162.80M
2023-12-31$151,000-$169.94M-$152.99M-$126.97M
2022-12-31$0-$114.79M-$104.68M-$71.30M
2021-12-31$20.10M-$56.37M-$58.74M-$63.17M
2020-12-31$0-$46.66M-$45.36M-$37.19M
2019-12-31$10.00M-$10.56M-$12.34M-$16.27M

Company filings

since Thu Sep 10

events

  • Regulation FD disclosure

    Regulation FD disclosure
    Sep 298-K
  • Regulation FD disclosure

    Regulation FD disclosure
    Sep 288-K
  • Other event

    Other event
    Sep 88-K
  • Regulation FD disclosure

    Regulation FD disclosure
    Aug 38-K
  • Results

    Results
    Aug 38-K
  • Regulation FD disclosure

    Regulation FD disclosure
    Jul 308-K

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

  • Tanini Annita

    Corp. Controller & VP, Finance

    Sale$12,595

    Aug 20, 4:10 PM ET

  • Lerner Lorena Raquel

    Chief Scientific Officer

    Sale$36,715

    Aug 20, 4:10 PM ET

  • Cho Esther

    Chief Legal Officer

    Sale$46,151

    Aug 20, 4:10 PM ET

  • Newton Charles W.

    Director

    Sale$5,675

    Aug 20, 4:10 PM ET

  • BIENAIME JEAN JACQUES

    Director

    Buy$10,270

    Aug 19, 4:10 PM ET

All insider trades for KROS

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

  • Point72

    Period Tue 30 Jun 2026

    0.0%Trimmed

All funds

News

Stories that named KROS, and the market events around them.

Sign in to see this

Board

Recent signals

Signals open up here once a member has posted about KROS.

Signals are informational.

Posts · 0

No posts yet.

Be the first to say something about KROS.

nakagai

Signals on KROS come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the KROS board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Keros Therapeutics, Inc. (KROS): SEC filings, financials and insider trades · Nakagai